Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Tec…


V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceutic…

POPULAR TAGS

argenx announces extension of therapeutic antibody alliance with Shire

Written by LVS on in the category news with the tags , .


Llama antibody developer for immune diseases and cancer argenx has announced the extension of its strategic partnership with Shire plc to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.

"The productivity of our collaboration with Shire has presented exciting product development opportunities in previously untapped target territory", said Debbie Allen, Senior VP Business Development of argenx. "Extension of this partnership provides both parties the potential to treat the pathophysiology of rare genetic diseases with potentially first-in-class antibody products".

A strong Belgian-Irish alliance

Under the terms of the agreement extension announced today, the parties will continue to progress preclinical development of the most promising programs to have arisen from the collaboration to date. Upon attainment of specified development criteria, Shire may exercise options - accompanied by a milestone payment to argenx on a per program basis - to take over product development and commercialization. argenx will thereafter receive milestone payments as programs proceed through clinical development and royalties on eventual product sales. argenx shall have the right to in-license any products falling outside Shire's areas of focus on pre-agreed financial terms. Further details of the extension agreement were not disclosed.

The initial agreement between Shire and argenx commenced in 2012 and was expanded into a strategic alliance in 2014 granting Shire licenses to the entire suite of argenx discovery technologies. argenx has since received licensing fees, research funding, and milestone payments from this collaboration.

Read more about: , .

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Tec…


V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceutic…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK XpandInnovation V-Bio Ventures Janssen Biowin KU Leuven UGent Itera Life Science Flanders.bio Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.